{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:21:33Z","timestamp":1787865693098,"version":"build-2784847793"},"reference-count":81,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["Tier 2"],"award-info":[{"award-number":["Tier 2"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Diabetic cardiomyopathy (DbCM) is commonly defined as ventricular dysfunction in a person living with diabetes in the absence of hypertension and\/or coronary artery disease (CAD). There is increasing recognition in the field that this is a poor definition to reflect the pathology of DbCM, as many individuals with diabetes (both type 1 and type 2) are often at risk of or have coexisting hypertension or CAD. On the contrary, there is increasing evidence that people living with diabetes, particularly in the early stages of disease progression, often have asymptomatic and subclinical diastolic dysfunction. Herein, we will interrogate the clinical evidence supporting the presence of diastolic dysfunction in people living with either type 1 or type 2 diabetes in the absence of hypertension and\/or CAD, and whether diastolic dysfunction should be a central feature in how we clinically define DbCM. Clinical agreement on how we define and interpret the pathology of DbCM is necessary should the field aim to develop specific pharmacotherapies for this disorder. DbCM should not be confused with heart failure with preserved ejection fraction (HFpEF), despite the latter also being characterized by diastolic dysfunction. Nonetheless, it will be imperative to understand whether DbCM can be a precursor toward the progression of HFpEF in people living with diabetes, as that may further reinforce the clinical importance of managing diastolic dysfunction in the population with diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title\/>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title\/>\n                  <\/jats:sec>","DOI":"10.2337\/dbi26-0002","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T21:31:33Z","timestamp":1780781493000},"page":"1371-1380","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":1,"title":["Focusing on Diastolic Dysfunction to Achieve Consensus With the Term Diabetic Cardiomyopathy"],"prefix":"10.2337","volume":"75","author":[{"given":"Alexa N.","family":"King","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta, Canada"},{"name":"Alberta Diabetes Institute, University of Alberta , Edmonton, Alberta, Canada"},{"name":"Cardiovascular Research Institute, University of Alberta , Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9574-5707","authenticated-orcid":false,"given":"John R.","family":"Ussher","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta, Canada"},{"name":"Alberta Diabetes Institute, University of Alberta , Edmonton, Alberta, Canada"},{"name":"Cardiovascular Research Institute, University of Alberta , Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"2026082716465729200_B1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2213-8587(25)00299-2","article-title":"11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050","volume":"14","author":"Genitsaridi","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026082716465729200_B2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11892-013-0380-1","article-title":"Is the risk and nature of CVD the same in type 1 and type 2 diabetes?","volume":"13","author":"Duca","year":"2013","journal-title":"Curr Diab Rep"},{"key":"2026082716465729200_B3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(10)62299-4","article-title":"Cardiovascular safety and diabetes drug development","volume":"377","author":"Drucker","year":"2011","journal-title":"Lancet"},{"key":"2026082716465729200_B4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2337\/dbi23-0019","article-title":"Redefining diabetic cardiomyopathy: perturbations in substrate metabolism at the heart of its pathology","volume":"73","author":"Heather","year":"2024","journal-title":"Diabetes"},{"key":"2026082716465729200_B5","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ Res"},{"key":"2026082716465729200_B6","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2021.08.020","article-title":"Prevalence and prognostic implications of diabetes with cardiomyopathy in community-dwelling adults","volume":"78","author":"Segar","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026082716465729200_B7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(54)90924-1","article-title":"Diabetic angiopathy: a specific vascular disease","volume":"266","author":"Lundbaek","year":"1954","journal-title":"Lancet"},{"key":"2026082716465729200_B8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"2026082716465729200_B9","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.2337\/diacare.26.10.2791","article-title":"Diabetes and idiopathic cardiomyopathy: a nationwide case-control study","volume":"26","author":"Bertoni","year":"2003","journal-title":"Diabetes Care"},{"key":"2026082716465729200_B10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12049","article-title":"Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension","volume":"15","author":"Landsberg","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026082716465729200_B11","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"2026082716465729200_B12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00125-010-1682-3","article-title":"Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis","volume":"53","author":"von Bibra","year":"2010","journal-title":"Diabetologia"},{"key":"2026082716465729200_B13","doi-asserted-by":"crossref","first-page":"H176","DOI":"10.1152\/ajpheart.00058.2022","article-title":"Guidelines on models of diabetic heart disease","volume":"323","author":"Heather","year":"2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026082716465729200_B14","doi-asserted-by":"crossref","first-page":"108935","DOI":"10.1016\/j.celrep.2021.108935","article-title":"FoxO1 inhibition alleviates type 2 diabetes-related diastolic dysfunction by increasing myocardial pyruvate dehydrogenase activity","volume":"35","author":"Gopal","year":"2021","journal-title":"Cell Rep"},{"key":"2026082716465729200_B15","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.2337\/diabetes.53.9.2366","article-title":"Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob\/ob mouse hearts","volume":"53","author":"Mazumder","year":"2004","journal-title":"Diabetes"},{"key":"2026082716465729200_B16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/cvr\/cvp017","article-title":"Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding","volume":"82","author":"Wright","year":"2009","journal-title":"Cardiovasc Res"},{"key":"2026082716465729200_B17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/01.CIR.0000127959.28627.F8","article-title":"Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women","volume":"109","author":"Peterson","year":"2004","journal-title":"Circulation"},{"key":"2026082716465729200_B18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/CIRCRESAHA.119.316260","article-title":"Noninvasive in vivo assessment of cardiac metabolism in the healthy and diabetic human heart using hyperpolarized 13C MRI","volume":"126","author":"Rider","year":"2020","journal-title":"Circ Res"},{"key":"2026082716465729200_B19","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jacc.2009.04.074","article-title":"Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging","volume":"54","author":"Rijzewijk","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026082716465729200_B20","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.2337\/db14-1560","article-title":"Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: a combined 13C hyperpolarized magnetic resonance and echocardiography study","volume":"64","author":"Le Page","year":"2015","journal-title":"Diabetes"},{"key":"2026082716465729200_B21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026082716465729200_B22","first-page":"140","article-title":"The GLP-1 receptor agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy","volume":"37","author":"Almutairi","year":"2021","journal-title":"Can J Cardiol"},{"key":"2026082716465729200_B23","doi-asserted-by":"crossref","first-page":"e240032","DOI":"10.1530\/JOE-24-0032","article-title":"Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner","volume":"262","author":"Chan","year":"2024","journal-title":"J Endocrinol"},{"key":"2026082716465729200_B24","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00125-005-1821-4","article-title":"Diabetic cardiomyopathy in uncomplicated type 2 diabetes is associated with the metabolic syndrome and systemic inflammation","volume":"48","author":"Diamant","year":"2005","journal-title":"Diabetologia"},{"key":"2026082716465729200_B25","doi-asserted-by":"crossref","first-page":"e104771","DOI":"10.1371\/journal.pone.0104771","article-title":"NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model","volume":"9","author":"Luo","year":"2014","journal-title":"PLoS One"},{"key":"2026082716465729200_B26","doi-asserted-by":"crossref","first-page":"115292","DOI":"10.1016\/j.bcp.2022.115292","article-title":"Blockage of MyD88 in cardiomyocytes alleviates cardiac inflammation and cardiomyopathy in experimental diabetic mice","volume":"206","author":"Luo","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"2026082716465729200_B27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/CIRCULATIONAHA.107.763730","article-title":"Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus","volume":"118","author":"Levy","year":"2008","journal-title":"Circulation"},{"key":"2026082716465729200_B28","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00125-019-4828-y","article-title":"Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis","volume":"62","author":"Teng","year":"2019","journal-title":"Diabetologia"},{"key":"2026082716465729200_B29","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.3390\/ijms24108604","article-title":"The role of cardiac fibrosis in diabetic cardiomyopathy: from pathophysiology to clinical diagnostic tools","volume":"24","author":"Pan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026082716465729200_B30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/j.2040-4603.2015.tb00624.x","article-title":"Extracellular matrix communication and turnover in cardiac physiology and pathology","volume":"5","author":"Takawale","year":"2015","journal-title":"Compr Physiol"},{"key":"2026082716465729200_B31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.lfs.2013.01.003","article-title":"Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts","volume":"92","author":"Fowlkes","year":"2013","journal-title":"Life Sci"},{"key":"2026082716465729200_B32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00018-024-05558-9","article-title":"The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy","volume":"82","author":"Kuo","year":"2025","journal-title":"Cell Mol Life Sci"},{"key":"2026082716465729200_B33","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/cvr\/cvae210","article-title":"Fibroblast-specific TGF-\u03b2 signaling mediates cardiac dysfunction, fibrosis, and hypertrophy in obese diabetic mice","volume":"120","author":"Tuleta","year":"2024","journal-title":"Cardiovasc Res"},{"key":"2026082716465729200_B34","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.2337\/db11-0549","article-title":"TRB3 gene silencing alleviates diabetic cardiomyopathy in a type 2 diabetic rat model","volume":"60","author":"Ti","year":"2011","journal-title":"Diabetes"},{"key":"2026082716465729200_B35","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.diabres.2011.11.007","article-title":"Decrease in calcium-sensing receptor in the progress of diabetic cardiomyopathy","volume":"95","author":"Bai","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"2026082716465729200_B36","doi-asserted-by":"crossref","first-page":"118617","DOI":"10.1016\/j.biopha.2025.118617","article-title":"Gene and drug-mediated SERCA2a activation restores cardiac function and metabolic balance in diabetic mice","volume":"192","author":"Kang","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"2026082716465729200_B37","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"2026082716465729200_B38","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1161\/CIRCULATIONAHA.105.579268","article-title":"A clinician\u2019s guide to tissue Doppler imaging","volume":"113","author":"Ho","year":"2006","journal-title":"Circulation"},{"key":"2026082716465729200_B39","doi-asserted-by":"crossref","first-page":"H733","DOI":"10.1152\/ajpheart.00339.2017","article-title":"Guidelines for measuring cardiac physiology in mice","volume":"314","author":"Lindsey","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026082716465729200_B40","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026082716465729200_B41","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1161\/CIRCULATIONAHA.106.662882","article-title":"Global diastolic strain rate for the assessment of left ventricular relaxation and filling pressures","volume":"115","author":"Wang","year":"2007","journal-title":"Circulation"},{"key":"2026082716465729200_B42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jacc.2004.09.054","article-title":"Diastolic dysfunction and left atrial volume: a population-based study","volume":"45","author":"Pritchett","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026082716465729200_B43","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jacc.2016.12.037","article-title":"A test in context: E\/A and E\/e' to assess diastolic dysfunction and LV filling pressure","volume":"69","author":"Mitter","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026082716465729200_B44","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF00277478","article-title":"Impairment of diastolic function in middle-aged type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients free of cardiovascular disease","volume":"31","author":"Uusitupa","year":"1988","journal-title":"Diabetologia"},{"key":"2026082716465729200_B45","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.amjcard.2003.12.026","article-title":"Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus","volume":"93","author":"Boyer","year":"2004","journal-title":"Am J Cardiol"},{"key":"2026082716465729200_B46","first-page":"OC27","article-title":"Left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus and its association with age, gender, duration and glycosylated haemoglobin: a cross-sectional study","volume":"17","author":"Shukla","year":"2023"},{"key":"2026082716465729200_B47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/0975-3583.89805","article-title":"Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function","volume":"2","author":"Patil","year":"2011","journal-title":"J Cardiovasc Dis Res"},{"key":"2026082716465729200_B48","article-title":"Diastolic dysfunction in type 2 diabetes and its correlation with nephropathy and associated risk factors","author":"Kashish","year":"2025","journal-title":"Ann Afr Med."},{"key":"2026082716465729200_B49","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.2147\/DMSO.S421761","article-title":"Female is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes","volume":"16","author":"Wang","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2026082716465729200_B50","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.echo.2011.07.017","article-title":"Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy?","volume":"24","author":"Ernande","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"2026082716465729200_B51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jcjd.2024.11.003","article-title":"Cardiovascular and respiratory measures in adults with early-onset type 2 diabetes mellitus compared with matched controls","volume":"49","author":"Munoz","year":"2025","journal-title":"Can J Diabetes"},{"key":"2026082716465729200_B52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12933-021-01328-0","article-title":"A cross sectional study to compare cardiac structure and diastolic function in adolescents and young adults with youth-onset type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study","volume":"20","author":"Shah","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026082716465729200_B53","doi-asserted-by":"crossref","first-page":"603247","DOI":"10.3389\/fphys.2020.603247","article-title":"The impact of antidiabetic therapies on diastolic dysfunction and diabetic cardiomyopathy","volume":"11","author":"Gopal","year":"2020","journal-title":"Front Physiol"},{"key":"2026082716465729200_B54","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12872-016-0242-2","article-title":"Tissue Doppler imaging is a sensitive echocardiographic technique to detect subclinical systolic and diastolic dysfunction of both ventricles in type 1 diabetes mellitus","volume":"16","author":"Suran","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"2026082716465729200_B55","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2337\/diacare.27.8.1947","article-title":"Female children and adolescents with type 1 diabetes have more pronounced early echocardiographic signs of diabetic cardiomyopathy","volume":"27","author":"Suys","year":"2004","journal-title":"Diabetes Care"},{"key":"2026082716465729200_B56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12872-016-0288-1","article-title":"Early reduced myocardial diastolic function in children and adolescents with type 1 diabetes mellitus a population-based study","volume":"16","author":"Brunvand","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"2026082716465729200_B57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21767\/2576-1455.1000115","article-title":"Early detection of diastolic dysfunction in diabetic patients (single center cross sectional study)","volume":"2","author":"Ashour","year":"2018","journal-title":"J Heart Cardiovasc Res"},{"key":"2026082716465729200_B58","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"2026082716465729200_B59","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.3390\/jcm13185351","article-title":"Prevalence of cardiomyopathy in patients with type 1 diabetes mellitus","volume":"13","author":"Fabila-de la Cruz","year":"2024","journal-title":"J Clin Med"},{"key":"2026082716465729200_B60","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00431-007-0603-z","article-title":"Cardiovascular impairment in children, adolescents, and young adults with type 1 diabetes mellitus (T1DM)","volume":"167","author":"Vazeou","year":"2008","journal-title":"Eur J Pediatr"},{"key":"2026082716465729200_B61","doi-asserted-by":"crossref","first-page":"H2096","DOI":"10.1152\/ajpheart.00452.2009","article-title":"Type 1 diabetic cardiomyopathy in the Akita (Ins2WT\/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function","volume":"297","author":"Basu","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026082716465729200_B62","doi-asserted-by":"crossref","first-page":"H1196","DOI":"10.1152\/ajpheart.2000.278.4.H1196","article-title":"Contribution of malonyl-CoA decarboxylase to the high fatty acid oxidation rates seen in the diabetic heart","volume":"278","author":"Sakamoto","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026082716465729200_B63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0005-2760(89)90328-7","article-title":"Glucose oxidation rates in fatty acid-perfused isolated working hearts from diabetic rats","volume":"1006","author":"Wall","year":"1989","journal-title":"Biochim Biophys Acta"},{"key":"2026082716465729200_B64","doi-asserted-by":"crossref","first-page":"7850","DOI":"10.1111\/jcmm.15418","article-title":"FOXO1 contributes to diabetic cardiomyopathy via inducing imbalanced oxidative metabolism in type 1 diabetes","volume":"24","author":"Yan","year":"2020","journal-title":"J Cell Mol Med"},{"key":"2026082716465729200_B65","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fphys.2020.00124","article-title":"Defining the progression of diabetic cardiomyopathy in a mouse model of type 1 diabetes","volume":"11","author":"De Blasio","year":"2020","journal-title":"Front Physiol"},{"key":"2026082716465729200_B66","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12933-025-02995-z","article-title":"HFpEF as the predominant and underrecognized heart failure phenotype in type 2 diabetes: evidence from the DIABET-IC study","volume":"24","author":"Gil-Millan","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026082716465729200_B67","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","article-title":"Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review","volume":"73","author":"McHugh","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026082716465729200_B68","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026082716465729200_B69","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamacardio.2022.1916","article-title":"Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea","volume":"7","author":"Reddy","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026082716465729200_B70","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovi\u0107","year":"2015","journal-title":"Eur Heart J"},{"key":"2026082716465729200_B71","doi-asserted-by":"crossref","first-page":"e020811","DOI":"10.1161\/JAHA.121.020811","article-title":"Three-dimensional global left ventricular myocardial strain reduced in all directions in subclinical diabetic cardiomyopathy: a systematic review and meta-analysis","volume":"10","author":"Ghoreyshi-Hefzabad","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026082716465729200_B72","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.acvd.2011.11.007","article-title":"Diabetic cardiomyopathy: myth or reality?","volume":"105","author":"Ernande","year":"2012","journal-title":"Arch Cardiovasc Dis"},{"key":"2026082716465729200_B73","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1093\/eurheartj\/ehm361","article-title":"Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy","volume":"28","author":"Konduracka","year":"2007","journal-title":"Eur Heart J"},{"key":"2026082716465729200_B74","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1479164115579006","article-title":"Diabetic cardiomyopathy: an expression of stage B heart failure with preserved ejection fraction","volume":"12","author":"Lam","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"2026082716465729200_B75","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cardfail.2021.12.017","article-title":"Economic issues in heart failure in the United States","volume":"28","author":"Heidenreich","year":"2022","journal-title":"J Card Fail"},{"key":"2026082716465729200_B76","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026082716465729200_B77","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026082716465729200_B78","doi-asserted-by":"crossref","first-page":"e019995","DOI":"10.1161\/JAHA.120.019995","article-title":"Effects of sodium-glucose linked transporter 2 inhibition with ertugliflozin on mitochondrial function, energetics, and metabolic gene expression in the presence and absence of diabetes mellitus in mice","volume":"10","author":"Croteau","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026082716465729200_B79","first-page":"41","article-title":"Empagliflozin attenuates diabetic cardiomyopathy via inhibiting cardiomyocyte ferroptosis through the USP7\/NRF2 signaling pathway","volume":"44","author":"Cui","year":"2026","journal-title":"Antioxid Redox Signal"},{"key":"2026082716465729200_B80","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/db19-0991","article-title":"Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating Sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet\u2013induced obese mice","volume":"69","author":"Sun","year":"2020","journal-title":"Diabetes"},{"key":"2026082716465729200_B81","first-page":"100825","article-title":"Metformin alleviates diastolic dysfunction in mice with experimental diabetic cardiomyopathy","volume":"14","author":"Chan","year":"2025","journal-title":"J Mol Cell Cardiol Plus"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/75\/8\/1371\/876166\/dbi260002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/75\/8\/1371\/876166\/dbi260002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:47:10Z","timestamp":1787863630000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/75\/8\/1371\/169202\/Focusing-on-Diastolic-Dysfunction-to-Achieve"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":81,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,6,6]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi26-0002","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]}}}